KEDI Tesla Fixed Tech100 Index
The index comprises 100 U.S.-listed equities, with an enhanced weighting allocated to Tesla.
Sentiment Summary
Recent Events
Q2 2026 earnings release scheduled for July 27, 2026. Medium importance is estimated as investors will monitor the impact of recent acquisitions on the updated guidance, scheduled.
Netflix is expected to announce its Q2 2026 financial results on 2026-07-16 based on past reporting schedules; low impact is estimated as this is a routine announcement expected.
Second quarter 2026 earnings report scheduled for July 14, 2026. A price impact of at least 5% is estimated based on historical volatility; scheduled.
The spin-off of the Honeywell Aerospace business is scheduled to be completed on June 29, 2026. This major corporate action will change share counts and is expected to have a high price impact, scheduled.
Qualcomm has scheduled an Investor Day for June 24, 2026, where it is expected to provide updates on its strategy and long-term outlook, scheduled. Low importance is estimated as such events typically result in price impacts of at least 1%.
Quarterly dividend of $1.70 per share, ex-dividend date scheduled for 2026-06-12; price impact of at least 1% expected.
Adobe's Q2 2026 earnings release is scheduled.
First quarter fiscal year 2027 earnings report on June 9, 2026, scheduled.
Apple announced its annual Worldwide Developers Conference (WWDC) will begin on June 8, 2026, teasing major AI advancements for its software platforms. Low importance estimated as product announcements typically have a moderate immediate price impact scheduled.
Broadcom is expected to release its second-quarter fiscal 2026 earnings on June 4, 2026, scheduled. High importance is estimated as quarterly earnings reports for major tech firms typically result in price movements exceeding 10%.
Ex-dividend date for the quarterly dividend of $1.60 per share on June 4, 2026, which was declared on April 27, 2026. scheduled
Marvell's first quarter fiscal year 2027 earnings release and conference call on 2026-06-04 scheduled; low impact expected as a routine financial disclosure.
Q4 and Full Fiscal Year 2026 earnings release is scheduled.
Synopsys is scheduled to report its second quarter fiscal year 2026 financial results after market close on 2026-05-27, as announced on 2026-04-27, with a price impact ≥1% scheduled.
Workday is scheduled to announce its Q1 fiscal 2027 financial results on May 21, 2026. A price impact of at least 5% is estimated based on historical volatility during earnings releases scheduled.
Q2 2026 earnings release is scheduled for May 20, 2026. The company forecasts revenue of approximately $3.5 billion and adjusted EPS of $2.88. High importance is estimated due to the potential for 10% or more price impact scheduled.
NVIDIA's Q1 fiscal 2027 earnings release is scheduled for May 20, 2026. Low importance assigned as the announcement of an earnings date typically results in ~1% price impact, scheduled.
Fiscal Third Quarter 2026 financial results are set to be released after market close. Medium impact is estimated due to high investor anticipation following previous guidance cuts scheduled.
Baidu is scheduled to report its first quarter 2026 financial results before the U.S. market opens on May 18, 2026. Medium importance estimated due to typical earnings volatility, scheduled.
Applied Materials is scheduled to report its fiscal second quarter 2026 financial results after the market closes on May 14, 2026. A price impact of less than 1% is estimated for this routine scheduling announcement, scheduled.
Cisco is expected to report its Q3 FY2026 earnings results. The company has guided for revenue between $15.4 billion and $15.6 billion and non-GAAP EPS between $1.02 and $1.04. A Medium importance is estimated as earnings releases typically result in price movements exceeding 5%, scheduled.
First quarter 2026 earnings release and webcast on May 7, 2026, scheduled; high impact due to historical earnings volatility expected.
Datadog is scheduled to report its first quarter 2026 financial results before the U.S. financial markets open on May 7, 2026. High importance is estimated as earnings releases typically result in significant price movement scheduled.
Q1 2026 financial results and conference call scheduled for 2026-05-07. Analysts forecast revenue of ~$189M and an EPS loss of ~$0.08. High importance estimated as Q1 results and Neutron rocket updates typically drive >10% price volatility scheduled.
The release of Q4 and full fiscal year 2026 financial results on May 7, 2026, is expected to have a medium impact as it provides the final results for the fiscal year, scheduled.
Natera is expected to announce its Q1 2026 financial results scheduled. Scheduled earnings releases are key volatility events with an estimated 5% impact.
Gilead will release first-quarter 2026 financial results on 2026-05-07, scheduled.
Axon is scheduled to report its first quarter 2026 financial results on May 6, 2026, after the market closes; high importance is estimated as earnings releases typically drive significant price impact scheduled.
Fortinet is scheduled to release its Q1 2026 financial results after the market closes on May 6, 2026, expected. Earnings releases for major tech firms often result in price swings exceeding 10%.
First quarter 2026 earnings results scheduled for release after market close on 2026-05-06 scheduled.
Shopify is scheduled to announce its financial results for the first quarter of 2026 before markets open on May 5, 2026, followed by a conference call. High importance is assigned as historical earnings reports for Shopify frequently result in price movements exceeding 10%, scheduled.
Scheduled to report fiscal first quarter 2026 financial results after the market close. Analysts forecast revenue of approximately $9.84 billion. Quarterly earnings reports are estimated to have a medium impact on price volatility scheduled.
Palantir is scheduled to release its financial results for the first quarter of 2026 on Monday, May 4, 2026, after the close of U.S. markets; high impact is estimated due to typical earnings volatility, expected.
Vertex Pharmaceuticals is scheduled to announce its Q1 2026 financial results on May 4, 2026. Analysts forecast earnings of $4.17 to $4.43 per share. A price impact of ≥5% is expected based on historical earnings volatility, and the event is scheduled.
Linde is scheduled to release its first quarter 2026 financial results on May 1, 2026. Analysts forecast EPS of approximately $4.27. Importance is estimated as Medium, as earnings releases for a company of this size typically cause moderate price volatility. scheduled
Effective May 1, 2026, Baidu implemented an organizational restructuring by unifying its dual-track career development system (professional and management) into a single numerical job-level system to foster more versatile AI-focused talent.
Apple's fiscal Q2 2026 earnings report and conference call are scheduled for April 30, 2026. Analysts project revenue around $109.73 billion and EPS around $1.94 forecasted. High importance estimated due to historical volatility around earnings releases scheduled.
Alnylam Pharmaceuticals is scheduled to report its financial results for the first quarter of 2026 before the U.S. financial markets open, with a conference call at 8:30 AM ET. High importance is estimated as earnings reports for major biotech firms often result in ≥10% price swings, and the event is scheduled.
Amgen is scheduled to release its Q1 2026 financial results after the market close on April 30, 2026, followed by a conference call with investors, expected.
First quarter 2026 financial results are scheduled to be reported after the market closes on April 30, 2026. Impact is estimated as neutral pending the actual release, scheduled
Q3 fiscal 2026 earnings release scheduled for 2026-04-29. Analysts forecast EPS of $3.30 and revenue of $5.85 billion; high price impact of at least 10% expected.
Amazon is scheduled to report its Q1 2026 financial results after the market close on April 29, 2026, with analysts forecasting revenue of approximately $177-$188 billion, expected.
First quarter 2026 earnings results scheduled to be released after market close on April 29, 2026; high impact is anticipated due to guidance updates, scheduled.
Alphabet is scheduled to report its Q1 2026 financial results on April 29, 2026. Analysts forecast EPS of approximately $2.63 on revenues of $106.9 billion; high importance due to expected market volatility scheduled.
KLA is scheduled to report its third-quarter fiscal year 2026 results on April 29, 2026, scheduled. High importance is estimated as earnings reports for major semiconductor equipment firms typically trigger price movements exceeding 10%.
Meta is scheduled to release its Q1 2026 financial results after market close on April 29, 2026. Analysts forecast significant revenue growth alongside a major increase in AI-related capital expenditures, making this a critical update for investors. This event is scheduled.
Microsoft's fiscal third-quarter 2026 earnings are scheduled to be released after the market close on April 29, 2026. Analysts forecast revenue of approximately $81.4 billion and EPS of $4.06. High importance is estimated as earnings results for major tech firms frequently trigger price movements exceeding 10% based on cloud growth and AI guidance, scheduled.
Qualcomm is scheduled to release its second-quarter fiscal 2026 financial results after the market close on April 29, 2026, followed by a conference call, scheduled. High importance is estimated as earnings reports often lead to price movements exceeding 10%.
Regeneron is scheduled to report its first quarter 2026 financial and operating results before the U.S. financial markets open on April 29, 2026. High importance is estimated as earnings reports often trigger price movements exceeding 10%. The event is scheduled.
Sanofi's Annual General Meeting held on April 29, 2026, where shareholders were expected to approve the appointment of Belén Garijo as the new CEO. Estimated ≥10% impact due to major leadership change, scheduled.
Biogen is scheduled to report its Q1 2026 financial results before the market opens on April 29, 2026. Analysts forecast earnings of approximately $2.96-$3.03 per share and revenue of around $2.25 billion. Market reaction is estimated at 5% based on historical earnings volatility, forecasted and scheduled.
The U.S. FDA's Center for Drug Evaluation and Research (CDER) proposed the withdrawal of approval for Amgen's autoimmune drug Tavneos on April 28, 2026, citing a lack of substantial evidence of effectiveness and alleging that the original application contained untrue statements and manipulated data.
Q1 2026 earnings released. Revenue grew 16% YoY to $5.53B, but the company cut its full-year 2026 revenue growth forecast from low double-digits to high single-digits, citing impacts from the Middle East conflict.
Reported Q1 2026 revenue of $3.18 billion and adjusted EPS of $3.05, both beating analyst expectations, and provided Q2 2026 guidance above consensus. This significant beat and raise is estimated to have a price impact of ≥10%, expected.
Teradyne reported Q1 2026 results on 2026-04-28 with record revenue and earnings above guidance, but its Q2 2026 outlook implied a sequential slowdown; shares fell more than 8% in extended trading.
On April 28, 2026, the FDA announced that Amgen is participating in a new pilot program for real-time review of clinical trial data, which aims to accelerate drug development.
On April 28, 2026, NVIDIA announced a new 12GB VRAM configuration for its GeForce RTX 5070 laptop GPU to expand product options and address memory supply constraints. Low importance assigned as product SKU updates typically result in ~1% price impact.
Reported Q1 2026 revenue of $1.474 billion and non-GAAP EPS of $1.96 on April 27, 2026, both beating analyst expectations. The company also raised its full-year 2026 revenue guidance to a range of $6.125 billion to $6.225 billion but lowered its non-GAAP EPS forecast to account for acquisition-related dilution.
Mizuho analysts downgraded Adobe stock from "outperform" to "neutral" and lowered the price target, citing concerns about increased competition from AI-native tools.
Marvell canceled purchase orders with Poet Technologies on 2026-04-27; medium impact expected due to potential supply chain disruptions and legal concerns.
Microsoft and OpenAI announced a restructuring of their partnership on April 27, 2026. Microsoft's license for OpenAI's models becomes non-exclusive, and it will no longer pay a revenue share to OpenAI. Medium importance is estimated as this strategic shift in a core AI partnership is expected to impact investor sentiment by approximately 5%.
Intel launched a multi-tranche investment-grade bond sale to raise approximately $6.5 billion on 2026-04-27; analysts forecast a 1-2% price impact, which is estimated.
Alphabet announced an investment of up to $40 billion in AI startup Anthropic on April 25, 2026, deepening its partnership.
Stock surged over 10% after D.A. Davidson upgraded its rating to 'Buy' and raised its price target to $375, citing positive read-through from competitor Intel's strong earnings expected.
U.S. lawmakers advanced the 'MATCH Act' on April 24, 2026, which aims to further restrict exports of semiconductor manufacturing equipment, including ASML's DUV systems, to China. High importance estimated due to potential for >10% revenue impact.
Comcast is scheduled to report Q1 2026 financial results on 2026-04-23; analysts forecast revenue of $31.46 billion and adjusted EPS of $0.79, though year-over-year declines and significant price volatility are expected.
Intel reported Q1 2026 revenue of $13.6 billion and non-GAAP EPS of $0.29, significantly beating analyst consensus on 2026-04-23; analysts forecast a >10% price impact, which is estimated.
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Otarmeni, Regeneron's first-in-class gene therapy for treating an ultra-rare form of genetic hearing loss, on April 23, 2026. High importance is assigned due to the significant impact of a first-in-class therapy approval.
CrowdStrike launched Project QuiltWorks on April 23, 2026, a coalition with partners including OpenAI, Accenture, and IBM, to address vulnerabilities discovered by AI models; medium impact estimated due to the strategic importance of AI security collaborations.
A share buyback program of up to SEK 15 billion commenced on April 23, 2026. A price impact of at least 5% is estimated due to the significant scale of the capital return.
Reported Q1 2026 adjusted EPS of $2.45, beating analyst estimates of ~$2.33, but revenue of $9.14 billion missed expectations of ~$9.30 billion. The company reaffirmed its full-year 2026 guidance. This earnings release is expected to have a moderate market impact, expected.
Announced an agreement to sell its Warehouse and Workflow Solutions (WWS) business to American Industrial Partners as part of its ongoing portfolio transformation. The deal is expected to close in the second half of 2026. This divestiture is expected to have a moderate impact on the company's valuation, expected.
On April 23, 2026, Regeneron announced an agreement with the U.S. government to lower drug prices, removing a potential overhang for the company. Medium importance is estimated as this resolves a key regulatory risk.
Reported Q1 2026 results on April 23, 2026, with double-digit growth; sales reached €10.5B (+13.6% at CER) and business EPS was €1.88 (+14.0% at CER), exceeding expectations and reaffirming full-year guidance.
Cisco announced the Cisco Universal Quantum Switch, a working research prototype designed to connect different quantum systems and modalities. A Low importance is estimated as product prototypes typically have a price impact of at least 1%.
Announced a €74 million investment to expand its Irish operations, planning to add approximately 200 new roles by 2027 with a focus on engineering and AI development. Low importance estimated as this is a localized operational expansion.
Reported Q3 2026 (March quarter) financial results, with record revenue of $5.84 billion (up 24% YoY) and non-GAAP EPS of $1.47, beating analyst estimates of ~$1.36. The company also provided positive guidance for the next quarter, forecasting record revenue of $6.6 billion and EPS of $1.65.
Tesla reported Q1 2026 EPS of $0.41, beating analyst estimates. However, the company also announced a significant increase in its 2026 capital expenditure forecast to over $25 billion to fund AI and robotics, which is expected to result in negative free cash flow for the remainder of the year.
Reported Q1 2026 financial results on 2026-04-22 with revenue of $4.83 billion and EPS of $1.68, beating analyst expectations, and issued strong Q2 2026 guidance; estimated ≥10% price impact due to double beat and strong guidance expected.
Broadcom announced an expanded collaboration with Google Cloud on April 22, 2026, to provide network observability services and continue co-designing Google's custom Tensor Processing Units (TPUs). Medium importance is assigned based on an estimated 5% price impact.
Credo is scheduled to participate in the TSMC 2026 Technology Symposium starting April 22, 2026, to showcase its new OmniConnect Weaver memory solution and 224G PAM4 SerDes IP; this product showcase is expected to have a moderate impact on investor sentiment scheduled.
Announced the general availability of GPU Monitoring, a new product to help businesses manage the cost and performance of their GPU fleets for AI workloads.
Palantir announced on April 22, 2026, it was awarded a blanket purchase agreement worth up to $300 million by the US Department of Agriculture (USDA) to modernize farm services and data.
On April 22, 2026, the FDA approved Dupixent for use in young children with uncontrolled chronic spontaneous urticaria (CSU), expanding the market for the key drug. Medium importance is estimated due to the expansion of a major revenue driver.
Synopsys announced an expanded collaboration with TSMC on 2026-04-22 to advance AI and high-performance computing chip design using certified EDA flows and silicon-proven IP, with a price impact ≥5% expected.
Released the AMD Ryzen 9 9950X3D2 Dual Edition processor, the first desktop processor with dual AMD 3D V-Cache technology, targeting developers and creators. This product launch is estimated to have a low market impact expected.
Amgen announced the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, on April 22, 2026.
At the Annual General Meeting on April 22, 2026, shareholders approved a total 2025 dividend of €7.50 per share, a 17% increase, and authorized a new share buyback program. Low importance as dividend increases typically result in a 1-5% positive market reaction, estimated.
Announced the expansion of its product leadership team to accelerate innovation in its core platform and AI-powered capabilities. Low importance estimated as this is a routine organizational update.